Pharmaceutical Quality Success: It's All About Management - - BioPharm International

ADVERTISEMENT

Pharmaceutical Quality Success: It's All About Management


BioPharm International
Volume 21, Issue 4


Marta Jimenez-Aquino
In the last decade, the US Food and Drug Administration (FDA) issued consent decrees against several large pharmaceutical manufacturers because of serious quality and compliance issues. In most cases, the FDA cited fundamental failures in the quality system and the management of those systems. The impact of these compliance problems goes beyond the financial penalties and costs of litigation. They threaten patient safety, jeopardize the company's credibility with regulatory agencies, and damage its reputation with the public. For years, regulators have issued observations that cited specific failures of the quality organization representatives. Now, the regulators are stating that it is the role of the executive management, not solely the quality organization, to ensure compliance by providing leadership to the organization.

In the ICH Q10 guidline, Pharmaceutical Quality Systems, regulators clearly identify senior management as having the ultimate responsibility for ensuring the implementation of effective pharmaceutical quality systems, and for defining, communicating, and implementing system responsibilities throughout the company.1 Senior management includes individuals who have the authority to establish a quality system, approve changes, and assign prioritization of workloads, as well as those who have financial authority to allocate capital and human resources. In other words, executives. The regulators are stating that the executives' role is not only to ensure the financial health of the company, but also compliance, and ultimately, patient safety. Compliance is a fundamental responsibility that cannot be delegated.

TURNING RESPONSIBILITY INTO ACTION

Once executives understand their responsibility for ensuring quality compliance, how can they take action? There are five key practices that successful executives follow:

1. Express a clear vision. Engaged executives express a clear and compelling vision for the organization. They play a key role in designing the quality program and showing how it ensures business excellence.

2. Use processes to drive compliance. Efficient executives clearly define processes, create procedures, and ensure that they are followed.

3. Provide sufficient resources and set priorities. Sufficient resources in equipment, facilities, and qualified personnel must be readily available to execute the quality program. Because time and resources are finite, however, effective executives set priorities that balance routine operations with continuous improvement projects. They also monitor resources regularly to ensure they meet the organization's needs.

4. Establish performance metrics and monitor them continuously. Successful executives make sure that a solid system is in place to collect, analyze, and report on key drivers of business and compliance excellence. They use the results to design and implement process improvements as needed.

5. Establish clear expectations. Effective executives make sure that the organization has a set of standards that clarify and document values and expected behaviors, and help employees maintain quality over time.

According to the regulators, an effective quality program under engaged executive leadership and management is the solution to ensuring patient safety and meeting compliance needs. Executives who want to succeed and avoid the risks of noncompliance will embrace these ideas and boldly lead their organizations into the future.

Marta Jimenez-Aquino is a vice president, David W. Husman, PhD, is a principal consultant, and Thomas Feyerabend, Jr., is a principal consultant, all at PAREXEL Consulting, Lowell, MA, 978.275.0062,


REFERENCE

1. International Conference on Harmonization. Q10, Pharmaceutical quality systems, draft guideline, step 2 version. Geneva, Switzerland; 9 May 2007.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
Author Guidelines
Source: BioPharm International,
Click here